Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNG | P07510 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRND | Q07001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29013168 | 1.00 | LTA4H (0.49) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2626581 | 1.00 | LTA4H (0.49) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL29297444 | 0.99 | LTA4H (0.48) | LTA4HPOLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL23042207 | 0.96 | CHRNB4 (0.48) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18786733 | 0.96 | CHRNB4 (0.48) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20533938 | 0.96 | CHRNB4 (0.48) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22555041 | 0.89 | CHRNB2 (0.41) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA1 | |
| SCHEMBL31122920 | 0.85 | LTA4H (0.36) | LTA4HPOLBCHRNB4CHRNA3KMT2A | |
| SCHEMBL31122947 | 0.81 | SMYD2 (0.37) | LTA4HCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL21528056 | 0.81 | LTA4H (0.47) | LTA4HCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | LTA4H 4333/4885POLB 2036/4885CHRNB4 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.